glp-1 drug market competition 2025 Receptor Agonist Size, Share Market Overview: GLP-1 Agonists and

Investment Thesis GLP-1s, also known as glucagon-like peptide-1, is a medication used for weight loss and diabetes management

This unique mechanism is designed to combine the incretin effects of GLP-1 and GIP with the energy-expenditure benefits of glucagon receptor activation, thereby potentially achieving greater weight reduction and metabolic improvements compared with single- or dual-agonist therapies

Recent research like the work happening at the University of Alabama at Birmingham (UAB) is helping explain why these medications are so effective and how they affect not just metabolism, but the brain itself

doi: 10.3389/fendo.2026.1805015 Received 05 February 2026 Revised 06 March 2026 Accepted 12 March 2026 Published 26 March 2026 Volume 17 - 2026 Edited by Yuzuru Ohshiro, Omoromachi Medical Center, Japan Reviewed by Edward Wargent, University of Buckingham, United Kingdom Antonio Maria Labate, ASST Franciacorta, Italy Updates Copyright 2026 Alkhezi, Alfehaid, Alanezi, Alotaibi and Alshaya

Furthermore, GLP-1R activation activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway via G-protein coupled receptor subunits (Fletcher et al

Intriguingly, recent studies have expanded the therapeutic scope of GLP-1RAs to neuroinflammatory regulation, with promising therapeutic potential observed in neurodegenerative disorders including Alzheimers disease, Parkinsons disease, and amyotrophic lateral sclerosis [271, 272]